國家衛生研究院 NHRI:Item 3990099045/15921
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 907921      在线人数 : 893
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/15921


    题名: pH-responsive beta-glucans-complexed mRNA in LNPs as an oral vaccine for enhancing cancer immunotherapy
    其它题名: pH-responsive β-glucans-complexed mRNA in LNPs as an oral vaccine for enhancing cancer immunotherapy
    作者: Luo, PK;Ho, HM;Chiang, MC;Chu, LA;Chuang, YH;Lyu, PC;Hu, IC;Chang, WA;Peng, SY;Jayakumar, J;Chen, HL;Huang, MH;Sung, HW
    贡献者: National Institute of Infectious Diseases and Vaccinology
    摘要: mRNA vaccines for cancer immunotherapy are commonly delivered using lipid nanoparticles (LNPs), which, when administered intravenously, may accumulate in the liver, potentially limiting their therapeutic efficacy. To overcome this challenge, the study introduces an oral mRNA vaccine formulation tailored for efficient uptake by immune cells in the gastrointestinal (GI) tract, known for its high concentration of immune cells, including dendritic cells (DCs). This formulation comprises mRNA complexed with beta-glucans (beta Glus), a potential adjuvant for vaccines, encapsulated within LNPs (beta Glus/mRNA@LNPs). The beta Glus/mRNA complexes within the small compartments of LNPs demonstrate a distinctive ability to partially dissociate and reassociate, responding to pH changes, effectively shielding mRNA from degradation in the harsh GI environment. Upon oral administration to tumor-bearing mice, beta Glus/mRNA@LNPs are effectively taken up by intestinal DCs and local nonimmune cells, bypassing potential liver accumulation. This initiates antigen-specific immune responses through successful mRNA translation, followed by drainage into the mesenteric lymph nodes to stimulate T cells and trigger specific adaptive immune responses, ultimately enhancing antitumor effects. Importantly, the vaccine demonstrates safety, with no significant inflammatory reactions observed. In conclusion, the potential of oral beta Glus/mRNA@LNPs delivery presents a promising avenue in cancer immunotherapy, offering needle-free and user-friendly administration for widespread adoption and self-administration. Upon oral administration of beta Glus/mRNA@LNPs, the pH-responsive partial dissociation/reassociation behavior of beta Glus/mRNA complexes within LNPs effectively shields mRNA from degradation in the harsh gastrointestinal (GI) environment. beta Glus serve as both a protective agent and an adjuvant, facilitating stable delivery into GI-resident dendritic cells and non-antigen presenting cells for translation into tumor-associated antigens. This process initiates antigen-specific immune responses against tumors. image
    日期: 2024-06-19
    關聯: Advanced Materials. 2024 Jun 19;Article in Press.
    Link to: http://dx.doi.org/10.1002/adma.202404830
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0935-9648&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:001254141100001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85196772043
    显示于类别:[黃明熙] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI001254141100001.pdf9125KbAdobe PDF78检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈